Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Cancer Clinical Trial

Official title:

Understanding Quality of Life Among Patients With Cancer Receiving Palliative Care

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05331625
• Other study ID #: UPCC 11922
• Secondary ID: 850807
• Status: Recruiting
• Phase: N/A
• Start date: November 3, 2022
• Est. completion date: April 2025

Study information

• Verified date: December 2023
• Source: Abramson Cancer Center at Penn Medicine
• Contact: Nicholas S Bishop
• Phone: 215-573-0779
• Email: nicholas.bishop[@]pennmedicine.upenn.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized controlled trial will assess the effects on quality of life of two approaches to symptom management among new patients referred to a palliative care oncology clinic.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 208
• Est. completion date: April 2025
• Est. primary completion date: November 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be a new patient at an outpatient palliative care clinic

• Resident of Pennsylvania

• Over 18 years of age

Exclusion Criteria:

• Prior use of certain symptom focused therapies

• Currently pregnant

Related Conditions & MeSH terms

• Cancer

Intervention

Behavioral:
• Offering Additional Resources to Promote Symptom Management
Participants will be offered additional resources to promote symptom management.

Locations

Country	Name	City	State
United States	University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center at Penn Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quality of Life - McGill Quality of Life Questionnaire	Quality of life will be measured through the McGill Quality of Life Questionnaire Revised (MQOL-R). The questionnaire is 15 questions assessing overall and specific areas of quality of life.	Baseline - 16 weeks
Secondary	Feasibility of Accessing Additional Resources for Symptom Management	Feasibility will be measured by whether participants accessed the additional resources for symptom management.	Baseline - 16 weeks
Secondary	Acceptability of Accessing Additional Resources for Symptom Management	Acceptability will be measured by whether participants accessed the additional resources for symptom management.	Baseline - 16 weeks
Secondary	Symptom Severity	Symptom severity will be measured through the Edmonton Symptom Assessment System (ESAS). The survey is 10 questions assessing the severity of pain, nausea, depression, etc. on a 0 to 10 scale-in which a 0 representing best possible state/symptom absence and a 10 representing worst possible state.	Baseline - 16 weeks
Secondary	Medication Use	Medication use will be measured through a medication diary created for the study. The medication diary asks participants about recent medications, amounts, and dosages.	Baseline - 16 weeks
Secondary	Hospital-Free Days	Hospital-free days will be measured through examination of participant's electronic health record.	Baseline - 16 weeks
Secondary	Mortality	Mortality will be measured through examination of participant's electronic health record.	Baseline - 16 weeks